DOCSLIB.ORG

Adrenoceptor Pharmacology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adrenoceptor Pharmacology ADRENOCEPTOR PHARMACOLOGY Emma Robinson and Alan Hudson within each group have now been cloned and Psychopharmacology Unit pharmacologically characterised. Thea1- adrenoceptor Department of Pharmacology subtypes have been classified as theaa1A , 1B and a 1D - School of Medical Sciences adrenoceptor and thea2 -adrenoceptors have been University of Bristol, University Walk classified as thea2A (a2D species variation of the human BS8 1TD, UK aa2A),2B anda 2C -adrenoceptor. Dr Alan Hudson is Head of Preclinical Research b-Adrenoceptors are also heterogeneous in nature and for the Psychopharmacology Unit, Emma were again initially subdivided intobb - and - Robinson is a Teaching Assistant in the 12 adrenoceptors, on the basis of the relative potencies of Department of Pharmacology a series of catecholamines inin vitro and in vivo systems.3 Subsequently theb -adrenoceptors have Introduction been classified using functional studies, receptor binding and genetic techniques. Theb -adrenoceptor Adrenoceptors are membrane bound receptors located family is subdivided into three distinct subtypes, the b1- throughout the body on neuronal and non-neuronal andb2- adrenoceptors and the atypicalb3 - tissues where they mediate a diverse range of adrenoceptor.4 There is an additionalb -adrenoceptor responses to the endogenous catecholamines subtype which has been identified in cardiac tissue and noradrenaline and adrenaline. The adrenoceptor family is a putative, atypical subtype classified as theb4 - was first divided into two subtypes, theab - and - adrenoceptor.5 adrenoceptors as determined by pharmacological studies in isolated tissue.1 A quarter of a century later, a -Adrenoceptors thea -adrenoceptors were further subdivided based on 1 their anatomical location, witha -adrenoceptors located a1-Adrenoceptor subtypes on peripheral sympathetic nerve terminals designated Subdivision of thea1- adrenoceptors has been a2-adrenoceptors and those located post-synaptically facilitated by both pharmacological and molecular 2 designateda1 -adrenoceptors. This anatomical biological techniques.6 The initial classification of the classification rapidly gave way to the identification of aa11B-adrenoceptors asa1A and -subtypes was pharmacological differences between thea - determined from differences in the binding adrenoceptors, notably the ability of yohimbine and characteristics of the competitive antagonist WB 4101 rauwolscine to act asa2- adrenoceptor antagonists. and the site-directed alkylating agent Subsequent studies using pharmacological and chloroethylclonidine (CEC). From radioligand binding molecular biological techniques have further studies it was determined that thea1A -subtype has a subdivided thea -adrenoceptor family; three subtypes high affinity for WB 4101 and is CEC-insensitive, whilst Table 1.a1 -Adrenoceptor characteristics Receptor typea1A -Adrenoceptoraa1B -Adrenoceptor 1D -Adrenoceptor Selective agonistsoxymetazoline, A61603 none none Non-subtype selectivecirazoline , M-6434 , cirazoline, M-6434 , cirazoline, M-6434, agonists methoxamine, phenylephrine, methoxamine, phenylephrine, methoxamine, phenylephrine, Selective antagonistsRS 17053, WB 4101, CEC (irreversible) BMY 7378 , SKF105854, (S)-(+)-niguldipine, CEC (irreversible) 5-methylurapidil, SNAP5089, Rec152739, SB216469, Ro700004, KMD3213 Non-subtype selective corynanthine, prazosin corynanthine, prazosin corynanthine, prazosin antagonists 2+ 2+ Transduction activates Gp/q ,­­ PI turnover, [Ca ]i.c. , activates voltage-gated Ca channels mechanism Physiological function smooth muscle contraction, smooth muscle contraction smooth muscle contraction myocardial contraction (bold text denotes compounds available from Tocris) Tocris Cookson Ltd., UK Tocris Cookson Inc., USA Tel: + 44 (0)117 982 6551 Toll Free Tel: (800) 421-3701 Tel: (636) 207-7651 Fax: + 44 (0)117 982 6552 Toll Free Fax: (800) 483-1993 Fax: (636) 207-7683 e-mail: [email protected] e-mail: [email protected] e-mail: [email protected] 16 thea1B -subtype exhibits a low affinity for WB 4101 but is adrenoceptor mRNA in the hippocampus and cortex. sensitive to CEC (Table 1). These characteristics were Peripherala1 -adrenoceptors are located on both also shown in a variety of tissue preparations vascular and non-vascular smooth muscle where confirming the presence of functional receptor activation of the receptor results in contraction.17 On 7 subtypes. In addition, three different cDNAs which vascular smooth muscle thea1 -adrenoceptors are coded fora1 -subtypes were isolated. These have since located intrasynaptically where they mediate the been characterised and are believed to code for three response to endogenous neurotransmitter release. functionalaaa11A1B -adrenoceptors: the and -subtypes They are also located on the heart where they mediate a positive inotropic effect and on the liver where they as described above and a third subtype, thea1D which has a low affinity for oxymetazoline in contrast to the activate glycogen phosphorylation. With the availability of subtype selective compounds thea -subtype has a1A-subtype, and is only partially sensitive to CEC, thus 1A been shown to be responsible for the contraction of vas making it pharmacologically distinct from the a1B receptor.8 The putativea -adrenoceptor shows similar deferens smooth muscle. Vasoconstriction in some 1L 18 characteristics to theaa - and -adrenoceptor but blood vessels has been shown to bea1B -mediated 1A 1D 16, 19 exhibits a low affinity for prazosin and, as yet the gene and contraction of the rat aorta isa1D -mediated. has not been identified.9 Compounds displaying a high a -Adrenoceptors affinity for thea1 -adrenoceptor subtype compared to 2 other receptors include the agonists cirazoline and M- 6434 and antagonists such as prazosin and HEAT. a2-Adrenoceptor subtypes Thea -adrenoceptors are located on both pre and post These twoa1 -selective antagonists are also used as 2 radioligands for investigating the binding synaptic neurones where they mediate an inhibitory role in the central and peripheral nervous system.20 The characteristics ofa1 -adrenoceptors. However, heterogeneous nature of thea -adrenoceptor was first following the initial characterisation of thea1 - 2 adrenoceptor subtypes subtype selective agonists and determined from the different pharmacological profiles antagonists are now being developed which include the of the receptor between species and subsequent a -selective agonists A6160310 and oxymetazoline, 4 studies have revealed the presence of different 1A subtypes within the same tissue. Thus, on the basis of and theaa -selective antagonist RS17053.11 The - 1A 1B radioligand binding profiles, amino acid sequence and adrenoceptor subtype has a higher affinity for CEC than chromosomal location, four distinct subtypes of thea - thea -subtype but CEC also exhibits a similar affinity 2 1A adrenoceptor have been characterised.21 Thesea - for thea -subtype. However, antagonists selective for 2 1D adrenoceptor subtypes,aaa , , and a are found thea -subtype such as BMY7378 and SKF105854 are 2A 2B 2C 2D 1D in a variety of species and tissues and have been now available.12, 13 characterised using tissue and cell lines expressing Signal transduction mechanism only one subtype. Thea2D -subtype exhibits a distinct pharmacological profile but, from the sequence Thea -adrenoceptors mediate their response via G- 1 homology is believed to be a species variation of the protein coupled receptors through a G /G mechanism. pq 22 All the subtypes are coupled to phospholipase C and a2A-subtype and is not recognised as separate. Although selective compounds are now being activation of the receptor results in the production of IP3 and DAG. The production of these second messengers developed to differentiate between thea2 -adrenoceptor results in an activation of both voltage dependent and subtypes there is no ligand available that is highly independent Ca2+ channels as well as stimulation of selective in functional studies for thea2 -adrenoceptor subtypes. Characterisation is based on the affinity of a protein kinase C, phospholipase A2 and D, arachidonic acid release and cyclic AMP formation.14, 15 range of compounds which exhibit different affinities for the subtypes (Table 2). Oxymetazoline displays a Location and function higher affinity for thea2A/D -subtype whilst prazosin Thea1 -adrenoceptors are located in the central and exhibits a higher affinity for theaa2B -subtype. The 2C - peripheral nervous system. In the CNS they are subtype has a high affinity for prazosin and low affinity predominantly located post-synaptically where they for oxymetazoline, characteristic of thea2B - mediate an excitatory role. Following cloning of thea1 - adrenoceptor subtype but the affinity for yohimbine is adrenoceptor subtypes, mRNA studies have showna1 - characteristic of thea2A -subtype. The antagonist MK Table 2.a2 -Adrenoceptor characteristics Receptor typea2A -Adrenoceptoraa2B -Adrenoceptor 2C -Adrenoceptor (previous name) (aaa2A , 2D , 2- C10, RG20) ( a 2 -C2, RNG) ( a 2 -C4) Selective agonistsoxymetazoline (partial agonist), none none guanfacine Non-subtype selective UK 14,304 UK 14,304 UK 14,304 agonists Clonidine Clonidine Clonidine Selective antagonistsBRL 44408 , BRL 48962 ARC 239 , imiloxan rauwolscine , MK 912 Non-subtype selectiveRS 79948, yohimbine , RS 79948, yohimbine , RS 79948, yohimbine , antagonists RS 15385, RX821002, RS 15385, RX821002, RS 15385, RX821002, SKF 86466, MK-912, SKF 86466, MK-912, SKF
Load more

Recommended publications
  • ALPHA ADRENOCEPTORS and HUMAN SEXUAL FUNCTION Alan
    8 1995 Elsevier Science B. V. All rights reserved. The Pharmacology of Sexual Function and Dysfunction J. Bancroft, editor 307 ALPHA ADRENOCEPTORS AND HUMAN SEXUAL FUNCTION Alan J Riley Field Place, Dunsmore, Buckinghamshire, HP22 6QH, UK Introduction Sexual functioning involves complex physiological processes which rely on the interplay of many central and peripheral neurotransmitter systems. Disturbances in any one of these systems might be associated with disturbed sexual function which, when recognised, may be alleviated by appropriate pharmacological manipulation, although at the present time this is more hypothesis than reality, The sympathetic nervous system is involved actively at various levels in the normal control of sexual responses. The effects of sympathetic activation are mediated by the release of noradrenaline from nerve terminals and the increased secretion of adrenaline from the adrenal medulla. These catecholamines selectively activate specific cellular sites in target tissues known as adrenoceptors (previously termed adrenergic receptors) to mediate responses. Almost fifty years ago, Alquist realised that tissue responses to catecholamines were mediated through two distinct types of receptors which he designated a and/? [1]. This review focuses on the involvement of a-adrenoceptors in human sexual functioning and dysfunction. Alpha adrenoceptors are located both pre- and post- synaptically and they were classified as either ar or af adrenoceptors according to location; or, being postsynaptic and az presynaptic. This classification continues to be used in some texts. However, as highly specific and selective pharmacological tools became available, this locational subclassification is found not always to be appropriate. Nowadays, classification of a-adrenoceptors is more appropriately based on pharmacological activity and additional subtypes of a-adrenoceptors have been identified by radioligand binding and molecular biological techniques [2].
    [Show full text]
  • Characterisation of the Α1b-Adrenoceptor by Modeling, Dynamics and Virtual Screening Kapil Jain B.Pharm, M.S.(Pharm.)
    Characterisation of the α1B-Adrenoceptor by Modeling, Dynamics and Virtual Screening Kapil Jain B.Pharm, M.S.(Pharm.) A Thesis submitted for the degree of Master of Philosophy at The University of Queensland in 2018 Institute for Molecular Bioscience 0 Abstract G protein-coupled receptors (GPCRs) are the largest druggable class of proteins yet relatively little is known about the mechanism by which agonist binding induces the conformational changes necessary for G protein activation and intracellular signaling. Recently, the Kobilka group has shown that agonists, neutral antagonists and inverse agonists stabilise distinct extracellular surface (ECS) conformations of the β2-adrenergic receptor (AR) opening up new possibilities for allosteric drug targeting at GPCRs. The goal of this project is to extend these studies to define how the ECS conformation of the α1B-AR changes during agonist binding and develop an understanding of ligand entry and exit mechanisms that may help in the design of specific ligands with higher selectivity, efficacy and longer duration of action. Two parallel approaches were initiated to identify likely functional residues. The role of residues lining the primary binding site were predicted by online web server (Q-Site Finder) while secondary binding sites residues were predicted from molecular dynamics (MD) simulations. Predicted functionally significant residues were mutated and their function was established using FLIPR, radioligand and saturation binding assays. Despite the α1B-AR being pursued as a drug target for over last few decades, few specific agonists and antagonists are known to date. In an attempt to address this gap, we pursued ligand-based approach to find potential new leads.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse
    University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 2012 Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse Pradeep Kumar Vuppala University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Vuppala, Pradeep Kumar, "Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse" (2012). Electronic Theses and Dissertations. 731. https://egrove.olemiss.edu/etd/731 This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. METABOLISM AND PHARMACOKINETICS IN THE DEVELOPMENT OF NEW THERAPEUTICS FOR COCAINE AND OPIOID ABUSE A Dissertation presented in partial fulfillment of requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences in the Department of Pharmaceutics The University of Mississippi by PRADEEP KUMAR VUPPALA April 2012 Copyright © 2012 by Pradeep Kumar Vuppala All rights reserved ABSTRACT Cocaine and opioid abuse are a major public health concern and the cause of significant morbidity and mortality worldwide. The development of effective medication for cocaine and opioid abuse is necessary to reduce the impact of this issue upon the individual and society. The pharmacologic treatment for drug abuse has been based on one of the following strategies: agonist substitution, antagonist treatment, or symptomatic treatment. This dissertation is focused on the role of metabolism and pharmacokinetics in the development of new pharmacotherapies, CM304 (sigma-1 receptor antagonist), mitragynine and 7-hydroxymitragynine (µ-opioid receptor agonists), for the treatment of drug abuse.
    [Show full text]
  • Alpha^ and Beta^Blocking Agents: Pharmacology and Properties
    CURRENT DRUG THERAPY DONALD G. VIDT, MD AND ALAN BAKST, PharmD, EDITORS Alpha^ and beta^blocking agents: pharmacology and properties PROFESSOR B.N.C. PRICHARD • Adrenergic receptors have been separated into alpha and beta groups, which have then been further subdivided. Agents have been developed that block each type of receptor with varying degrees of specificity between the sub-types, leading to differences in pharmacodynamic profile. A more recent innovation has been the development of multiple action beta-blocking drugs, ie, those not only blocking the beta receptors but also posessing a peripheral vasodilator effect that may be due to alpha blockade, beta-2 stimulation, or a vasodilator action independent of either alpha or beta receptors. • INDEX TERMS: ALPHA BLOCKERS; BETA BLOCKERS; HYPERTENSION • CLEVE CLIN ] MED 1991; 58:33 7-350 HE CONCEPT that binding of Rosenblueth suggested that a transmitter released at catecholamines to receptors leads to differ- sympathetic nerve endings produced either inhibitory ing responses was first described by Langley, or excitatory responses as a result of combination with who in 1905 noted that a cell may make sympathin I or sympathin E at the receptor.3 Tmotor or inhibitory substances or both, and that "the The current classification of alpha and beta respon- effect of a nerve impulse depends upon the proportion ses is based on the classic work of Ahlquist,4 who of the two kinds of receptive substance which is af- studied six sympathomimetic amines and found two fected by the impulse."1 In 1906, Dale reported that patterns of reactivity. One group of actions, mediated ergot blocked the excitatory but not the inhibitory ac- by what were termed "alpha receptors," were principally tions of adrenaline.2 In 1933, Cannon and excitatory.
    [Show full text]
  • M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic
    M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats Geoffrey B. Varty, Ph.D., Vaishali P. Bakshi, Ph.D., and Mark A. Geyer, Ph.D. a In a recent study using Wistar rats, the serotonergic 5-HT2 1 receptor agonist cirazoline disrupts PPI. As risperidone a receptor antagonists ketanserin and risperidone reduced the and M100907 have affinity at the 1 receptor, a final study disruptive effects of the noncompetitive N-methyl-D- examined whether M100907 would block the effects of aspartate (NMDA) antagonist dizocilpine on prepulse cirazoline on PPI. Risperidone partially, but inhibition (PPI), suggesting that there is an interaction nonsignificantly, reduced the effects of dizocilpine in Wistar between serotonin and glutamate in the modulation of PPI. rats, although this effect was smaller than previously In contrast, studies using the noncompetitive NMDA reported. Consistent with previous studies, risperidone did antagonist phencyclidine (PCP) in Sprague–Dawley rats not alter the effects of dizocilpine in Sprague–Dawley rats. found no effect with 5-HT2 antagonists. To test the hypothesis Most importantly, M100907 pretreatment fully blocked the that strain differences might explain the discrepancy in effect of dizocilpine in both strains; whereas SDZ SER 082 these findings, risperidone was tested for its ability to had no effect. M100907 had no influence on PPI by itself reduce the PPI-disruptive effects of dizocilpine in Wistar and did not reduce the effects of cirazoline on PPI. These and Sprague–Dawley rats. Furthermore, to determine studies confirm the suggestion that serotonin and glutamate which serotonergic receptor subtype may mediate this effect, interact in modulating PPI and indicate that the 5-HT2A the 5-HT2A receptor antagonist M100907 (formerly MDL receptor subtype mediates this interaction.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Functional Evidence for Atypical Β-Adrenoceptors in Rat Isolated
    FUNCTIONAL EVIDENCE FOR ATYPICAL p-ADRENOCEPTORS IN RAT ISOLATED ARTERIES A thesis submitted by SONIA SOOCH for the degree of Doctor of Philosophy in the University of London. 1996 Department of Pharmacology University College London Gower Street London WCIE 6 BT ProQuest Number: 10055412 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10055412 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Since the original classification by Lands et al (1967a), it has become evident that not all (3-adrenoceptor mediated responses can be classified as either (3i or P 2, with the existence of an additional p-adrenoceptor subtype, referred to as the atypical or p 3-adrenoceptor. This p-adrenoceptor subtype has been identified in adipose and gastrointestinal tissue, as well as skeletal muscle and airway smooth muscle. The work presented in this thesis demonstrates the presence of atypical p-adrenoceptors in rat vasculature. The present in vitro results show that relaxations to isoprenaline in the rat thoracic aorta, mesenteric and pulmonary artery, are antagonized by propranolol in a non-competitive manner.
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • 33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline And
    J. Smooth Muscle Res. 33 : 99-106. 99 The )32 and [33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline and Salbutamol in Guinea Pig Taenia Caecum Katsuo KOIKE, Tsukasa IcHiNo, Takahiro HORINOUCHI and Issei TAKAYANAGI Departmentof Chemical Pharmacology, Toho University School of PharmaceuticalSciences, 2-2-1, Miyama,Funabashi, Chiba 274, Japan Abstract To understand the receptor subtypes responsible for /3adrenoceptormediated relaxa tion of guinea pig taenia caecum, we investigated the effects of isoprenaline and salbutamol . Isoprenaline and salbutamol caused dose-dependent relaxation of the guinea pig taenia caecum. Propranolol, bupranolol and butoxamine produced shifts of the concentration response curves for isoprenaline and salbutamol. Schild regression analyses carried out for propranolol against isoprenaline and salbutamol gave pA2 values of 8.43 and 8.88, respective ly. Schild regression analyses carried out for butoxamine against isoprenaline and sal butamol gave pA2 values of 6.46 and 6.68, respectively. Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 8.60 and 8.69, respectively. However, in the presence of 3 x 10' M atenolol, 10-4 M butoxamine and 10-6 M phentolamine to block the fir , /32 and a -adrenoceptor effects, respectively, Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 5.77 and 5.97, respectively. These results suggest that the relaxant responses to isoprenaline and salbutamol in the guinea pig taenia caecum are mediated by both the /.32 and the A-adrenoceptors. Key words : f2-adrenoceptor, A-adrenoceptor, isoprenaline, salbutamol , guinea pig taenia caecum Introduction The /3adrenoceptors were subclassified as and /32subtypes based on the agonist potency and tissue localization.
    [Show full text]